MediSix Therapeutics is an early-stage cell therapy company that is taking a novel approach to develop chimeric antigen receptor (“CAR”) T cells to target T cell lymphoma and leukemia.
Location: Singapore
Investors 1
| Date | Name | Website |
| 06.04.2022 | Lightstone... | lightstone... |
Mentions in press and media 1
| Date | Title | Description |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build. ClavystBio has committed US$220 million to date in investments to launch global ... |